JP2022532923A5 - - Google Patents
Info
- Publication number
- JP2022532923A5 JP2022532923A5 JP2021569268A JP2021569268A JP2022532923A5 JP 2022532923 A5 JP2022532923 A5 JP 2022532923A5 JP 2021569268 A JP2021569268 A JP 2021569268A JP 2021569268 A JP2021569268 A JP 2021569268A JP 2022532923 A5 JP2022532923 A5 JP 2022532923A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- membered
- haloalkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025164289A JP2026027223A (ja) | 2019-05-20 | 2025-09-30 | 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850061P | 2019-05-20 | 2019-05-20 | |
| US62/850,061 | 2019-05-20 | ||
| PCT/US2020/033746 WO2020236901A1 (en) | 2019-05-20 | 2020-05-20 | A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025164289A Division JP2026027223A (ja) | 2019-05-20 | 2025-09-30 | 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532923A JP2022532923A (ja) | 2022-07-20 |
| JP2022532923A5 true JP2022532923A5 (https=) | 2023-05-26 |
| JP7820798B2 JP7820798B2 (ja) | 2026-02-26 |
Family
ID=73458653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569268A Active JP7820798B2 (ja) | 2019-05-20 | 2020-05-20 | 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 |
| JP2025164289A Pending JP2026027223A (ja) | 2019-05-20 | 2025-09-30 | 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025164289A Pending JP2026027223A (ja) | 2019-05-20 | 2025-09-30 | 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12528808B2 (https=) |
| EP (1) | EP3972605A4 (https=) |
| JP (2) | JP7820798B2 (https=) |
| CN (1) | CN114096250B (https=) |
| CA (1) | CA3135592A1 (https=) |
| WO (1) | WO2020236901A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3135592A1 (en) | 2019-05-20 | 2020-11-26 | Xiaochao Ma | Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) |
| US11813257B2 (en) * | 2020-01-09 | 2023-11-14 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| CN120965522B (zh) * | 2025-10-20 | 2026-02-17 | 兰树化妆品股份有限公司 | 一种Fmoc-Tea-OH及其制备方法和在多肽合成中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| FR2765243B1 (fr) | 1997-06-30 | 1999-07-30 | Usinor | Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction |
| US9114102B2 (en) | 2007-11-07 | 2015-08-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of inhibiting ABCG2 and related treatments |
| WO2009088831A2 (en) | 2008-01-03 | 2009-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of inhibiting abcg2 and other treatment methods |
| US9056111B1 (en) | 2011-09-21 | 2015-06-16 | Stc.Unm | Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment |
| EP3054951A4 (en) * | 2013-10-07 | 2017-05-10 | Millennium Pharmaceuticals, Inc. | Inhibitor of breast cancer resistance protein (bcrp) |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| EP3341079A4 (en) | 2015-08-25 | 2019-05-08 | President and Fellows of Harvard College | METHOD AND COMPOSITIONS RELATED TO DIAGNOSIS AND TREATMENT OF CANCER |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| CN106191061B (zh) | 2016-07-18 | 2019-06-18 | 暨南大学 | 一种特异靶向人ABCG2基因的sgRNA导向序列及其应用 |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| CA3135592A1 (en) | 2019-05-20 | 2020-11-26 | Xiaochao Ma | Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp) |
-
2020
- 2020-05-20 CA CA3135592A patent/CA3135592A1/en active Pending
- 2020-05-20 EP EP20809953.1A patent/EP3972605A4/en active Pending
- 2020-05-20 US US17/612,638 patent/US12528808B2/en active Active
- 2020-05-20 WO PCT/US2020/033746 patent/WO2020236901A1/en not_active Ceased
- 2020-05-20 CN CN202080049199.0A patent/CN114096250B/zh active Active
- 2020-05-20 JP JP2021569268A patent/JP7820798B2/ja active Active
-
2025
- 2025-09-30 JP JP2025164289A patent/JP2026027223A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6905075B2 (ja) | 腫瘍の治療または予防のための併用療法 | |
| Venditto et al. | Cancer therapies utilizing the camptothecins: a review of the in vivo literature | |
| ES2275931T5 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| US6352996B1 (en) | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs | |
| US11241500B2 (en) | HSP90-targeting conjugates and formulations thereof | |
| ES2737692T3 (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas | |
| JP2022532923A5 (https=) | ||
| TWI893202B (zh) | 缺氧活化的dna烷化劑及其醫藥用途 | |
| TW202508589A (zh) | 包含ａｔｒ抑制劑及ｐａｒｐ抑制劑之組合及其使用方法 | |
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| JP2003523381A (ja) | 投与レジメン | |
| KR20120046099A (ko) | 섬유화를 억제하고 섬유화 질병을 치료하는 방법 | |
| US20070248692A1 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| EA032867B1 (ru) | Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты | |
| JP2021512110A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| CN107249638A (zh) | 阿匹莫德用于治疗肾癌 | |
| JP2003525255A (ja) | ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤 | |
| CA3115068A1 (en) | Method for preparing and delivering bisantrene formulations | |
| JP2026035569A (ja) | オキサゾリジノン化合物、オキサゾリジノン化合物を含むリポソーム組成物、およびそれらの使用方法 | |
| KR20210008527A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법 | |
| CA2522980A1 (en) | Water soluble wortmannin derivatives | |
| US10548861B2 (en) | Use of ureidomustine (BO-1055) in cancer treatment | |
| Huang et al. | New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors | |
| JP2006518726A5 (https=) | ||
| JP2025508548A (ja) | 淡明細胞型腎細胞癌の治療 |